Bright Minds Biosciences Net Debt Growth & History (DRUG)

Bright Minds Biosciences's net debt was −$82.8M for fiscal 2025.

View full Bright Minds Biosciences company overview

Bright Minds Biosciences annual net debt history

Bright Minds Biosciences annual net debt

Fiscal yearPeriod endedNet debtChangeGrowth
20252025-09-30−$82.8M−$77.2M
20242024-09-30−$5.6M$1.1M
20232023-09-30−$6.7M$4.8M
20222022-09-30−$11.5M$8.3M
20212021-09-30−$19.8M

Bright Minds Biosciences net debt trends

Between the periods ended 2021-09-30 and 2025-09-30, Bright Minds Biosciences's net debt decreased from −$19.8M to −$82.8M, a change of −$63.0M. The latest reported quarter, Q3 2026, shows −$307.8M.

About the metric

What net debt means

Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.

Calculation and source

How net debt is calculated

TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Bright Minds Biosciences source filings ↗

Community posts

It’s quiet here.

No posts about DRUG yet. Start the conversation.

Write the first post